Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Jayakrishnan B, Hoke DE, Langendorf CG, Buckle AM, Rowley MJ.

PLoS One. 2011 Apr 8;6(4):e18411. doi: 10.1371/journal.pone.0018411.

2.

The PEVKEK region of the pyridoxal phosphate binding domain of GAD65 expresses a dominant B cell epitope for type 1 diabetes sera.

Tong JC, Myers MA, Mackay IR, Zimmet PZ, Rowley MJ.

Ann N Y Acad Sci. 2002 Apr;958:182-9.

PMID:
12021103
3.
4.
5.

Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.

Ujihara N, Daw K, Gianani R, Boel E, Yu L, Powers AC.

Diabetes. 1994 Aug;43(8):968-75.

PMID:
8039604
6.

Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes.

Hampe CS, Hammerle LP, Bekris L, Ortqvist E, Kockum I, Rolandsson O, Landin-Olsson M, Törn C, Persson B, Lernmark A.

J Clin Endocrinol Metab. 2000 Dec;85(12):4671-9.

PMID:
11134126
7.
8.

Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition.

Primo ME, Anton EA, Villanueva AL, Poskus E, Ermácora MR.

Clin Immunol. 2003 Jul;108(1):38-45.

PMID:
12865069
9.

Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.

Seissler J, Amann J, Mauch L, Haubruck H, Wolfahrt S, Bieg S, Richter W, Holl R, Heinze E, Northemann W, et al.

J Clin Invest. 1993 Sep;92(3):1394-9.

10.

Immune reactivity to GAD25 in type 1 diabetes mellitus.

Chessler SD, Hampe CS, Ortqvist E, Simonson WT, Bekris L.

Autoimmunity. 2002 Aug;35(5):335-41.

PMID:
12515288
11.

Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes.

Lühder F, Schlosser M, Mauch L, Haubruck H, Rjasanowski I, Michaelis D, Kohnert KD, Ziegler M.

Autoimmunity. 1994;19(2):71-80.

PMID:
7772705
12.

Antibodies to glutamic acid decarboxylase and P2-C peptides in sera from coxsackie virus B4-infected mice and IDDM patients.

Hou J, Said C, Franchi D, Dockstader P, Chatterjee NK.

Diabetes. 1994 Oct;43(10):1260-6.

PMID:
7523207
13.
14.

Glutamic acid decarboxylase-67 (GAD67): expression relative to GAD65 in human islets and mapping of autoantibody epitopes.

Cram DS, Faulkner-Jones B, Kun J, Harrison LC.

Endocrinology. 1995 Mar;136(3):1111-9.

PMID:
7532577
15.

COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity.

Fenalti G, Hampe CS, Arafat Y, Law RH, Banga JP, Mackay IR, Whisstock JC, Buckle AM, Rowley MJ.

Diabetes. 2008 May;57(5):1293-301. doi: 10.2337/db07-1461. Epub 2008 Jan 9.

16.

Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.

Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum WA, Banga JP.

J Clin Endocrinol Metab. 1997 Aug;82(8):2664-70.

PMID:
9253351
17.

Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase.

Hagopian WA, Michelsen B, Karlsen AE, Larsen F, Moody A, Grubin CE, Rowe R, Petersen J, McEvoy R, Lernmark A.

Diabetes. 1993 Apr;42(4):631-6.

PMID:
8454115
18.

Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.

Ziegler B, Schlosser M, Lühder F, Strebelow M, Augstein P, Northemann W, Powers AC, Ziegler M.

Acta Diabetol. 1996 Sep;33(3):225-31.

PMID:
8904930
19.

Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders.

Powers AC, Bavik K, Tremble J, Daw K, Scherbaum WA, Banga JP.

Clin Exp Immunol. 1999 Dec;118(3):349-56.

20.

Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.

Kim J, Namchuk M, Bugawan T, Fu Q, Jaffe M, Shi Y, Aanstoot HJ, Turck CW, Erlich H, Lennon V, Baekkeskov S.

J Exp Med. 1994 Aug 1;180(2):595-606.

Supplemental Content

Support Center